Microdrop Mydrin-P
Phase 1Small molecule
Microdrop Mydrin-P is one of 28 small molecule programs targeting Retinopathy of Prematurity. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Retinopathy of Prematurity
#DrugCompanyPhaseTrials
1Ketalar
AAultman Health Foundation
Approved
Advil
KKenvue Brands
Approved
Lucentis
RochePhase 3
Decadron
AAspen Global Incorporated
Approved
Eylea
RegeneronPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Eylea
BayerPhase 3
Inderal
WWyeth-Lederle Vaccines
Phase 2
Smoflipid
FFresenius
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Microdrop Mydrin-P. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- TThe University of Hong Kong